



---

## Uploaded to VFC Website

► November 2012 ◄

---

This Document has been provided to you courtesy of Veterans-For-Change!

Feel free to pass to any veteran who might be able to use this information!

For thousands more files like this and hundreds of links to useful information, and hundreds of "Frequently Asked Questions, please go to:

[Veterans-For-Change](#)

---

*Veterans-For-Change is a 501(c)(3) Non-Profit Corporation  
Tax ID #27-3820181*

### **If Veteran's don't help Veteran's, who will?**

We appreciate all donations to continue to provide information and services to Veterans and their families.

[https://www.paypal.com/cgi-bin/webscr?cmd=\\_s-xclick&hosted\\_button\\_id=WGT2M5UTB9A78](https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=WGT2M5UTB9A78)

---

**Note:** VFC is not liable for source information in this document, it is merely provided as a courtesy to our members.



**Item ID Number** 05647

**Not Scanned**

**Author**

**Corporate Author**

**Report/Article Title** House of Representatives Bill H.R. 3297, 99th Congress, 1st Session, To require the Administrator of the Veterans' Affairs to provide for an Epidemiological Study of the Gender-Specific Effect of Exposure to the Herbicide Known as Agent Orange on Female Veterans

**Journal/Book Title**

**Year** 1985

**Month/Day** September 12

**Color**

**Number of Images** 6

**Description Notes**

99TH CONGRESS  
1ST SESSION

# H. R. 3297

To require the Administrator of the Veterans' Administration to provide for an epidemiological study of the gender-specific effect of exposure to the herbicide known as Agent Orange on female veterans.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 12, 1985

Ms. KAPTUR (for herself, Mr. EDWARDS of California, Mr. EDGAR, Mr. DASCHLE, Mr. PENNY, and Mr. EVANS of Illinois) introduced the following bill; which was referred to the Committee on Veterans' Affairs

---

## A BILL

To require the Administrator of the Veterans' Administration to provide for an epidemiological study of the gender-specific effect of exposure to the herbicide known as Agent Orange on female veterans.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. AGENT ORANGE STUDY FOR FEMALE VETERANS.**

4       (b) REQUIREMENT FOR EPIDEMIOLOGICAL STUDY.—

5       (1) The Administrator of Veterans' Affairs shall provide for  
6       the conduct of an epidemiological study of any long-term ad-  
7       verse gender-specific health effects in females of service in  
8       the Armed Forces of the United States in the Republic of

- 1 Vietnam during the period of the Vietnam conflict as such
- 2 health effects may result from exposure to—

(A) phenoxy herbicides (including the herbicide known as Agent Orange); and

(B) the class of chemicals known as the dioxins produced during the manufacture of such herbicides.

7       (2) In providing for such study, the Administrator may  
8 expand the scope of the study to include an evaluation of any  
9 long-term adverse gender-specific health effects in females of  
10 such service as such health effects may result from other fac-  
11 tors involved in such service (including exposure to other her-  
12 bicides, chemicals, medications, or environmental hazards or  
13 conditions).

14 (3) The Administrator may also include in the study an  
15 evaluation of the means of detecting and treating adverse  
16 gender-specific health effects found through the study.

17 (4) The Administrator shall provide for the study to be  
18 conducted through contracts or agreements with public or  
19 private agencies or persons.

(b) FUNCTIONS OF OFFICE OF TECHNOLOGY ASSESSMENT.—(1) The study required by subsection (a) shall be conducted in accordance with a protocol approved by the Director of the Office of Technology Assessment.

24 (2) The Director shall monitor the conduct of such study  
25 in order to assure compliance with such protocol.

1       (3)(A) Concurrent with the approval or disapproval of  
2 any protocol under paragraph (1), the Director shall submit  
3 to the appropriate committees of Congress a report—

4                 (i) explaining the basis for the Director's action in  
5 approving or disapproving the protocol; and

6                 (ii) providing the Director's conclusions regarding  
7 the scientific validity and objectivity of the protocol.

8       (B) If the Director has not approved such a protocol  
9 during the 180 days following the date of the enactment of  
10 this Act, the Director—

11                 (i) shall submit to the appropriate committees of  
12 Congress a report describing the reasons why the Di-  
13 rector has not given such approval; and

14                 (ii) shall submit to such committees an update  
15 report on such initial report each 60 days thereafter  
16 until such a protocol is approved.

17       (4) The Director shall submit to the appropriate commit-  
18 tees of Congress, at each of the times specified in the second  
19 sentence of this paragraph, a report on the Director's moni-  
20 toring of the conduct of such study pursuant to paragraph (2).

21 A report under the preceding sentence shall be submitted—

22                 (A) before the end of the six-month period begin-  
23 ning on the date of the approval of the protocol by the  
24 Director;

1                   (B) before the end of the 12-month period begin-  
2                   ning on such date; and

3                   (C) annually thereafter until the study is complet-  
4                   ed or terminated.

5                   (c) DURATION OF STUDY.—The study conducted pursu-  
6                   ant to subsection (a) shall be continued for as long after the  
7                   submission of the first report under subsection (d)(1) as the  
8                   Administrator may determine reasonable in light of the possi-  
9                   bility of developing through such study significant new infor-  
10                  mation on the long-term gender-specific adverse health ef-  
11                  fects in females of exposure to dioxins.

12                  (d) REPORTS TO CONGRESS.—(1) Not later than 24  
13                  months after the date of the approval of the protocol pursuant  
14                  to subsection (b)(1) and annually thereafter, the Administra-  
15                  tor shall submit to the appropriate committees of Congress a  
16                  report containing—

17                   (A) a description of the results thus far obtained  
18                  under the study conducted pursuant to such subsection;  
19                  and

20                   (B) such comments and recommendations for ad-  
21                  ministrative or legislative action, or both, as the Ad-  
22                  ministrator considers appropriate in light of such re-  
23                  sults.

24                  (2) Not later than 90 days after the submission of each  
25                  report under paragraph (1), the Administrator shall publish in

1 the Federal Register, for public review and comment, a de-  
2 scription of any action that the Administrator proposes to  
3 take with respect to programs administered by the Veterans'  
4 Administration. Each such description shall include a justifi-  
5 cation or rationale for any such action the Administrator pro-  
6 poses to take. Any such proposal shall be based on the results  
7 described in the report under paragraph (1) and the com-  
8 ments and recommendations on that report and any other  
9 available pertinent information.

10 (3) The requirement in paragraph (1) for the submission  
11 of annual reports expires upon the submission of a report  
12 after the completion of the study under subsection (a).

13 (e) BUDGET ACT PROVISIONS.—(1) This section does  
14 not authorize the enactment of new budget authority for a  
15 fiscal year before fiscal year 1987.

16 (2) A contract to carry out the study under subsection  
17 (a) may be entered into only to the extent that—

18 (A) appropriated funds are available to carry out  
19 the contract; or

20 (B) the contract provides that the obligation of the  
21 United States to make payments under the contract is  
22 contingent upon the availability of appropriated funds  
23 for such payments.

24 (f) DEFINITION.—For the purposes of this section, the  
25 term “gender-specific health effects in females” includes ef-

1 fects on female reproductive capacity, reproductive organs,  
2 and reproductive outcomes, effects on female-specific organs  
3 and tissues, and other effects unique to the physiology of fe-  
4 males.

